Nintedanib is an inhibitor of PDGFR, vascular endothelial growth factor receptor (VEGFR), and fibroblast growth factor receptor (FGFR) [65] and this specificity of inhibition may be key to its effects on AEx-IPF. This evidence concerns the gene PDGFRB and idiopathic pulmonary fibrosis.